AIRSUPRA® (albuterol/budesonide) now available as the first and …
2024年1月22日 · AstraZeneca announces AIRSUPRA ® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older. 1.
Avillion, AstraZeneca asthma rescue treatment given FDA approval
2025年1月17日 · A first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide (an anti-inflammatory...
Airsupra (PT027) approved in the US for asthma - AstraZeneca
2023年1月11日 · Airsupra is a first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US. It is being developed by AstraZeneca and Avillion.
On April 28, 2023, the FDA approved AstraZeneca’s Symbicort Aerosphere (budesonide/formoterol), for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). — Symbicort Aerosphere is not indicated for the relief of acute bronchospasm or for the treatment of asthma.
AIRSUPRA® (albuterol/budesonide) demonstrated statistically …
2024年10月7日 · Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to …
FDA Approves AIRSUPRA, a New Quick-Relief Medicine for Adults …
AIRSUPRA is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US. It …
AstraZeneca and Avillion’s asthma rescue treatment granted FDA …
2023年1月12日 · AstraZeneca (AZ) and Avillion’s Airsupra, formerly known as PT027, has been approved by the US Food and Drug Administration (FDA) as the first and only rescue medication for as-needed use to reduce the risk of asthma exacerbations for adults with asthma.
AstraZeneca announces initiation of THARROS – a Phase III clinical ...
WILMINGTON, Del., March 13, 2024 -- (BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy...
Documents available - AstraZeneca clinical trials
A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma (VATHOS).
New Asthma Inhaler Combines Quick-Relief Albuterol and …
A new medication supports treating asthma symptoms and inflamed airways at the same time. The new treatment option is AIRSUPRA®. The medication involves one inhaler device. It combines: Albuterol, a short-acting beta-agonist (SABA) Budesonide, an inhaled corticosteroid; AIRSUPRA is a quick-relief or rescue inhaler. It is not a daily controller ...